Cancer drug RVU120 gets extended trial for ongoing patients
Disease control
ENROLLING_BY_INVITATION
This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC